Vanderbilt University Medical Center was recently named a center of excellence for hypertrophic cardiomyopathy by the Hypertrophic Cardiomyopathy Association.

Vanderbilt has reached a new milestone in implanting CardioMEMS remote cardiac monitoring devices.

Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.

Brandon Cochran, a 39-year-old real estate agent in Louisville, Kentucky, was at home with his family in October 2020 when he went into cardiac arrest. His implanted defibrillator shocked him back to life, and he was hospitalized for seven months.

The Structural Heart and Valve Center at Vanderbilt Heart and Vascular Institute (VHVI) has recently completed multiple groundbreaking transcatheter clinical trial procedures treating severe regurgitation of the mitral and tricuspid valves, a continuation of a decade of research that is revolutionizing the treatment of these conditions.

The Anticoagulation Clinic at Vanderbilt Heart and Vascular Institute (VHVI) has been designated an Anticoagulation Center of Excellence by the Anticoagulation Forum, one of only three in Tennessee.

Matthews Chacko, MD, has joined Vanderbilt Heart and Vascular Institute as an assistant professor of Medicine, an interventional cardiologist and the director of peripheral vascular interventions.